Hemangioblastoma patient typing management system

Abstract

The invention provides a hemangioblastoma patient typing management system. The hemangioblastoma patient typing management system includes a hemangioblastoma typing diagnostic kit, and a patient datamanagement device, wherein the hemangioblastoma typing diagnostic kit includes a genomic imprinting subtype hemangioblastoma diagnostic reagent, a hemangioblastoma recurrence tracking diagnostic reagent and a gene mutation subtype hemangioblastoma diagnostic reagent, for detecting blood or tissue samples of a patient so as to obtain a detection result; and the patient data management device is provided with a patient information storage unit, a management-side screen storage unit, a criterion storage unit, a management measure storage unit, a management-side input display unit, a data analysisunit, a management guide generation unit, and a management-side control unit.

Description

technical field [0001] The invention relates to a disease management system, in particular to a hemangioblastoma patient type management system. Background technique [0002] Von Hippel-Lindau (VHL) disease (OMIM 193300) is an autosomal dominant syndrome with the potential to develop a variety of benign and malignant neoplasms in various organ systems. Its inheritance results from germline mutations in the chromosomally located VHL gene and exhibits significant phenotypic variability, age-dependent penetrance, and interfamilial variation. Tumors characteristic of VHL include: central nervous system (CNS) and retinal hemangioblastomas (HBs), clear cell renal carcinoma, neuroendocrine tumors, pancreatic cysts, pheochromocytoma, etc. Most patients with VHL will be infected with CNS-HBs, with an incidence ranging from 34.3% to 72%. [0003] VHL disease occurs in all ethnic groups around the world. Both sexes are equally affected, with a prevalence rate of 1:30,000 to 1:50,000...

Images